Trial Profile
A clinical study of Multi-antibody cocktail therapy as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 20 Mar 2020
At a glance
- Drugs Multi antibody cocktail therapy Regeneron Pharmaceuticals (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 20 Mar 2020 New trial record
- 17 Mar 2020 According to an Regeneron Pharmaceuticals media release, this study is expected to begin by early(beginning) summer 2020.
Most Recent Events
Trial Overview
Purpose
This study will evaluate Multi-antibody cocktail therapy as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | prevention, treatment | - |
Subjects
- Subject Type patients & volunteers
- Sex male & female
Trial Details
Organisations
- Affiliations Regeneron Pharmaceuticals
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I
- Location USA
- Focus Therapeutic Use
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| Multi antibody cocktail therapy Regeneron PharmaceuticalsPrimary Drug | Parenteral |
-
|
Multi-antibody cocktail therapy
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 20 Mar 2020 | New trial record | New trial record Updated 20 Mar 2020 |
| 17 Mar 2020 | Other trial event | According to an Regeneron Pharmaceuticals media release, this study is expected to begin by early(beginning) summer 2020. Updated 20 Mar 2020 |
References
-
Regeneron Pharmaceuticals. Regeneron Announces Important Advances in Novel COVID-19 Antibody Program. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG